Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck

尼妥珠单抗 医学 西妥昔单抗 内科学 肿瘤科 皮疹 头颈部癌 放射治疗 头颈部鳞状细胞癌 安慰剂 放化疗 胃肠病学 外科 癌症 表皮生长因子受体 病理 结直肠癌 替代医学
作者
Marta Osorio Rodríguez,Teresa Cruz Rivero,Ramón Del Castillo Bahi,Carlos Roca Muchulí,Miguel Azcue Bilbao,Elia Nenínger Vinageras,José Alert,Julio Jiménez Galainena,Edmundo Rodríguez,Elías Gracia,Bárbara M. Mulén Nápoles,Bárbara Wilkinson,Esther Lucía de Armas,Kirenia Pérez,Idael Pineda Callejo,Milagros Frómeta,Idrissa Leonard,Vladimir Mullens,Carmen Viada,Patricia Lorenzo-Luaces
出处
期刊:Cancer Biology & Therapy [Taylor & Francis]
卷期号:9 (5): 343-349 被引量:181
标识
DOI:10.4161/cbt.9.5.10981
摘要

The prognosis of patients with advanced head and neck cancer remain dismal. For this tumor type, elevated levels of EGFR are associated with a shorter disease free survival and time to treatment failure, reflecting a more aggressive phenotype. Nimotuzumab is a humanized monoclonal antibody that recognizes domain III of the extracellular region of the EGFR, within an area that overlaps with both the surface patch recognized by cetuximab and the binding site for EGF. In order to assess the efficacy of nimotuzumab in combination with radiotherapy, a controlled, double blind, randomized clinical trial was conducted in 106 advanced squamous cell carcinoma of the head and neck patients, mostly, unfit for chemoradiotherapy. Control patients received a placebo and radiotherapy. Treatment was safe and the most frequent adverse events consisted on grade I or II asthenia, fever, headache and chills. No skin rash was detected. A significant complete response rate improvement was found in the group of patients treated with nimotuzumab as compared to the placebo. In the intent to treat analysis, a trend towards survival benefit for nimotuzumab treated subjects was found. The survival benefit became significant when applying the Harrington-Fleming test, a weighted log-rank that underscores the detection of differences deferred on time. In addition, a preliminary biomarker investigation showed a significant survival improvement for nimotuzumab treated patients as compared to controls for subjects with EGFR positive tumors. All patients showed a quality of life improvement and a reduction of the general and specific symptoms of the disease.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
xzy666的应助被zhiwei采纳,获得10
2秒前
lizi完成签到,获得积分10
3秒前
3秒前
4秒前
5秒前
FashionBoy的应助被苗条书桃采纳,获得30
6秒前
牛牛发布了新的文献求助10
6秒前
周芷卉发布了新的文献求助10
7秒前
tlc_191026发布了新的文献求助10
8秒前
9秒前
daomaihu发布了新的文献求助100
9秒前
9秒前
无花果的应助被激动的绿竹采纳,获得10
9秒前
Stella发布了新的文献求助10
10秒前
10秒前
爆米花的应助被六六大顺采纳,获得10
10秒前
复古红完成签到,获得积分10
10秒前
哇晒完成签到 ,获得积分10
10秒前
nhzz2023发布了新的文献求助10
10秒前
10秒前
Lucas的应助被ZZ采纳,获得10
10秒前
10秒前
香蕉觅云的应助被applecat147采纳,获得10
11秒前
12秒前
12秒前
12秒前
歪歪歪完成签到 ,获得积分10
13秒前
14秒前
脑洞疼的应助被陈哈哈采纳,获得10
14秒前
科研通AI6.3的应助被牧百川采纳,获得10
14秒前
vancomycin完成签到,获得积分10
14秒前
文艺山灵完成签到 ,获得积分10
14秒前
15秒前
15秒前
15秒前
INFINITY发布了新的文献求助10
15秒前
INFINITY发布了新的文献求助10
15秒前
INFINITY发布了新的文献求助30
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183449
求助须知:如何正确求助?哪些是违规求助? 9572834
关于积分的说明 21827509
捐赠科研通 7780646
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480371